Johnson & Johnson (NYSE:JNJ) is one of the 15 Best Stocks to Buy According to Billionaire Ray Dalio. Johnson & Johnson ...

Royalty Pharma has made another play in the autoimmune space, this time crowning Johnson & Johnson as the beneficiary. Royalty and J&J have agreed to co-fund the development of a chronic autoimmune ...

Johnson & Johnson (JNJ) stock is up 62% over the last twelve months. For a healthcare giant typically filed under "boring and ...

So far, Tecvayli has had an incremental contribution to 2025 sales of $670M; while Darzalex Faspro saw $14.4B in 2025 sales.

Have you been searching for a stock that might be well-positioned to maintain its earnings-beat streak in its upcoming report ...

Looking ahead to 2030, our model projects JNJ could trade at an average price of $339.68, with a potential range between $254 ...

Consensus projects Johnson & Johnson's EPS CAGR of 8.9% (2026–2030), with forward P/E compressing from 20.8x to 14.8x. Read ...

Johnson & Johnson (NYSE: JNJ) recently released its Q1 earnings, surpassing analyst estimates on both revenue and earnings. The company posted adjusted earnings of $2.77 per share on revenue of $21.9 ...

Royalty Pharma plc (Nasdaq: RPRX) today announced a research and development (R&D) co-funding agreement with Johnson & Johnson for a total of $500 million in 2026 and 2027 to advance the development ...

Question: What caused JNJ stock to rise 70% since early 2025? The short answer: investor sentiment played a major role, with actual business performance taking a supportive role. JNJ increased from ...

Johnson & Johnson (NYSE:JNJ) ranks among the best most active stocks to buy right now. On March 13, Johnson & Johnson ...